Adoptive immunotherapy for cancer: harnessing the T cell response

By N. Restifo, M. Dudley, S. Rosenberg. Nature reviews. Immunology, 2012

1,673 citations recorded by the source corpus.

Immunotherapy based on the adoptive transfer of naturally occurring or gene-engineered T cells can mediate tumour regression in patients with metastatic cancer. Here, we discuss progress in the use of adoptively transferred T cells, focusing on how they can mediate tumour cell eradication. Recent advances include more accurate targeting of antigens expressed by tumours and the associated vasculature, and the successful use of gene engineering to re-target T cells before their transfer into the patient. We also describe how new research has helped to identify the particular T cell subsets that can most effectively promote tumour eradication.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/758aa5b618e7dad15dd463e516dc9d02f4e58140

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “Over time, much progress has been made in this field [167], due to • optimization of the treatment protocol (e.”
The Two Faces of IL-6 in the Tumor Microenvironment (2014, background): “While adoptive T cell transfer therapy offers great promise, durable response rates following treatment in patients are <25% [51,84].”
Nanomedicine in cancer therapy (2023, background): “118 T-cell-based immunotherapies are emerging a powerful clinical tool for cancer therapy.”